NASDAQ:ARDS

Aridis Pharmaceuticals Earnings Date & Estimates

Aridis Pharmaceuticals logo
$0.0001 0.00 (0.00%)
As of 01:31 PM Eastern

Aridis Pharmaceuticals is estimated to report earnings on Thursday, November 19, 2026.

What Analysts Expect from Aridis Pharmaceuticals

Aridis Pharmaceuticals is expected to post earnings of -$0.5960 per share on revenue of $267 thousand. Aridis Pharmaceuticals has beaten the consensus EPS estimate in 2 of its last 8 quarters.

Consensus Estimates

Consensus EPS
-$0.5960
Expected Revenue
$267 thousand

Recent Track Record

Last Reported
Q3 2023
Last Quarter EPS
-$0.02
Last Quarter Revenue
$420 thousand
EPS Beat Rate
2 of last 8 quarters

Aridis Pharmaceuticals Earnings FAQ

Aridis Pharmaceuticals (NASDAQ:ARDS) is estimated to report earnings on Thursday, November 19, 2026. This date is estimated from past reporting schedules and may change once the company confirms it.

Analysts expect Aridis Pharmaceuticals to post earnings of -$0.5960 per share for the quarter.

The consensus revenue estimate for Aridis Pharmaceuticals is $267 thousand for the quarter.

Aridis Pharmaceuticals Earnings Headlines

Aridis Pharmaceuticals, Inc. (ARDS) - Yahoo Finance
Aridis Provides Corporate Update
Top Trader Reveals Stunning Black Friday Deal
Others paid $500 for the Snapback Indicator. This Black Friday, it's available for just $7. Base Camp Trading's Thomas Wood calls it one of the firm's most powerful proprietary trading indicators, and says the company has never run a deal like this before. There are no strings attached, just a steep Black Friday discount on a tool built for traders.tc pixel
See More Aridis Pharmaceuticals Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Aridis Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Aridis Pharmaceuticals and other key companies, straight to your email.

About Aridis Pharmaceuticals

Aridis Pharmaceuticals (NASDAQ:ARDS) is a biopharmaceutical company focused on developing antibody-based treatments for infectious diseases, particularly serious bacterial and respiratory infections. Its work has included therapies intended to complement antibiotics by targeting toxins or other components of disease-causing bacteria.

The company’s research programs have included AR-301, a monoclonal antibody targeting Staphylococcus aureus alpha toxin, investigated as a potential treatment for severe pneumonia. Aridis has also developed other antibody candidates for infectious diseases using its antibody-discovery technologies.

Founded in 2003 and based in San Jose, California, Aridis was founded by Vu Truong, who has served as the company’s chief executive officer. Its development programs have been conducted primarily in the United States.

View Aridis Pharmaceuticals Profile